Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar 24;22(3):114.
doi: 10.1208/s12249-021-01980-5.

Nanoparticulate tablet dosage form of lisofylline-linoleic acid conjugate for type 1 diabetes: in situ single-pass intestinal perfusion (SPIP) studies and pharmacokinetics in rat

Kishan S Italiya  1 , Arihant K Singh  1 , Deepak Chitkara  1 , Anupama Mittal  2
Affiliations

Nanoparticulate tablet dosage form of lisofylline-linoleic acid conjugate for type 1 diabetes: in situ single-pass intestinal perfusion (SPIP) studies and pharmacokinetics in rat

Kishan S Italiya et al. AAPS PharmSciTech. .

Abstract

Lisofylline (LSF) is an anti-inflammatory molecule with high aqueous solubility and rapid metabolic interconversion to its parent drug, pentoxifylline (PTX) resulting in very poor pharmacokinetic (PK) parameters, necessitating high dose and dosing frequency. In the present study, we resolved the physicochemical and pharmacokinetic limitations associated with LSF and designed its oral dosage form as a tablet for effective treatment in type 1 diabetes (T1D). Self-assembling polymeric micelles of LSF (lisofylline-linoleic acid polymeric micelles (LSF-LA PLM)) were optimized for scale-up (6 g batch size) and lyophilized followed by compression into tablets. Powder blend and tablets were evaluated as per USP. LSF-LA PLM tablet so formed was evaluated for in vitro release in simulated biological fluids (with enzymes) and for cell viability in MIN-6 cells. LSF-LA PLM in tablet formulation was further evaluated for intestinal permeability (in situ) along with LSF and LSF-LA self-assembled micelles (SM) as controls in a rat model using single-pass intestinal perfusion (SPIP) study. SPIP studies revealed 1.8-fold higher oral absorption of LSF-LA from LSF-LA PLM as compared to LSF-LA SM and ~5.9-fold higher than LSF (alone) solution. Pharmacokinetic studies of LSF-LA PLM tablet showed greater Cmax than LSF, LSF-LA, and LSF-LA PLM. Designed facile LSF-LA PLM tablet dosage form has potential for an immediate decrease in the postprandial glucose levels in patients of T1D.

Keywords: LSF-LA PLM; SPIP; nanoparticulate tablet; pharmacokinetics; phenol red; simulated biological fluids; type 1 diabetes.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. McCarty MF, O’Keefe JH, DiNicolantonio JJ. Pentoxifylline for vascular health: a brief review of the literature. Open Heart. 2016;3(1):e000365. - PubMed - PMC
    1. Yang Z, Chen M, Nadler JL. Lisofylline: a potential lead for the treatment of diabetes. Biochem Pharmacol. 2005;69(1):1–5. - PubMed
    1. Italiya KS, Mazumdar S, Sharma S, Chitkara D, Mahato RI, Mittal A. Self-assembling lisofylline-fatty acid conjugate for effective treatment of diabetes mellitus. Nanomedicine: NBM. 2019;15(1):175–87. https://doi.org/10.1016/j.nano.2018.09.014 . - DOI
    1. Chen M, Yang Z, Wu R, Nadler JL. Lisofylline, a novel antiinflammatory agent, protects pancreatic β-cells from proinflammatory cytokine damage by promoting mitochondrial metabolism. Endocrinology. 2002;143(6):2341–8. https://doi.org/10.1210/endo.143.6.8841 . - DOI - PubMed
    1. Świerczek A, Wyska E, Pociecha K, Baś S, Mlynarski J. Influence of inflammatory disorders on pharmacokinetics of lisofylline in rats: implications for studies in humans. Xenobiotica. 2019;49(10):1209–20. - PubMed

MeSH terms

LinkOut - more resources